MAPK3 and inflammatory breast carcinoma: Only with the presence of ER-α36 but not ER-α66, the treatment of estradiol and anti-estrogenic agents led to rapid activation of p-ERK1/2 and substantial increase of cell migration and invasiveness in inflammatory breast cancer [42].